RxDoctor Payments Data

Lisa Poston

Family · Florence, SCNPI 1366909434

Payments from drug & device makers

$989in general payments, 2019–2025

Across 52 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$129
  • Novo Nordisk$115
  • Lilly USA, LLC$68
  • Amgen$67
  • Corcept Therapeutics$66
  • Abbott$55
  • plus $489 from 17 others

What the payments were for

  • Food & beverage$989100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$989 in reported general payments places this provider in the 65th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$712
Medicare patients
11
Services billed
99

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$92,203
RybelsusSemaglutide18$49,566
TrulicityDulaglutide20$40,055
MounjaroTirzepatide21$39,149
FarxigaDapagliflozin Propanediol16$26,497
LipitorAtorvastatin Calcium16$20,893
JanuviaSitagliptin Phosphate12$19,193
EliquisApixaban13$18,693
LinzessLinaclotide11$15,666
XareltoRivaroxaban11$12,848
NorvascAmlodipine Besylate18$12,797
Repatha SureclickEvolocumab11$12,602
MyrbetriqMirabegron13$11,267
CozaarLosartan Potassium11$5,409
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$115$141,77069 claims
Lilly USA, LLCTrulicity, Mounjaro$68$79,20441 claims
PfizerLipitor, Eliquis$14$39,58629 claims
AstraZenecaFarxiga$38$26,49716 claims
AbbVieLinzess$35$15,66611 claims
Astellas Pharma US IncMyrbetriq$20$11,26713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,248 family providers in South Carolina.

Other family in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →